<DOC>
	<DOC>NCT01363466</DOC>
	<brief_summary>GYNECO 02 hypothesis is that hysterectomy reduces the possibility of local or loco-regional relapse, especially in patient with a reduced metastatic risk and who received a local chemoradiation therapy with an increase of radiotherapy doses (45 grays).</brief_summary>
	<brief_title>Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Squamous Cell</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Adenosquamous</mesh_term>
	<criteria>operable Stage IB2/II Cervical Cancer adenocarcinoma, squamous cell or adenosquamous carcinoma Patient between 18 and 70 years old No lomboaortic lymph node invasion at baseline Previous 45 grays external pelvic radiation with concomitant chemotherapy (cisplatin 40 mg/m2/week corresponding to 5 cycles) Followed by a 15 grays uterovaginal brachytherapy, eventually combined with a 6th cycle of chemotherapy (cisplatin 40 mg/m2) with a pelvic boost if lymph node or parametrial invasion No macroscopic residual tumor after 6 to 8 weeks after brachytherapy. Other tumor histology (neuroendocrine) Stage &gt; II (FIGO 1995) at baseline Patient with remaining cervical cancer (after subtotal hysterectomy)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>